Full research 

  • Gao GF, Thurn M, Wendt B, Parnham MJ, Wacker MG (2020); A sensitive in vitro performance assay reveals the in vivo drug release mechanisms of long-acting medroxyprogesterone acetate microparticles, Int. J. Pharm. (10.1016/j.ijpharm.2020.119540)
  • Nagpal S and Braner S, Modh H, Tan AXX, Mast MP, Chichakly K, Albrecht V, Wacker MG (2020); A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2020.06.004)
  • Hering I, Eilebrecht E, Parnham MJ, Günday-Türeli N, Türeli AE, Weiler M, Schäfers C, Fenske M, Wacker MG (2020)Evaluation of potential environmental toxicity of polymeric nanomaterials and surfactants,  Environ. Toxicol. Pharmacol. (10.1016/j.etap.2020.103353)
  • Jablonka L, Ashtikar M, Gao GF, Thurn M, Modh H, Wang JW, Preuß A, Scheglmann D, Albrecht V, Röder B, Wacker MG (2020); Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2020.02.001)
  • Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG (2019); Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques, Pharmaceutics (10.3390/pharmaceutics11100489
  • Wallenwein CM and Villa Nova M, Janas C, Jablonka L, Gao GF, Thurn M, Albrecht V, Wiehe A, Wacker MG (2019); A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2019.08.010)
  • Jablonka L, Ashtikar M, Gao G, Jung F, Thurn M, Preuß A, Scheglmann D, Albrecht V, Röder B, Wacker MG (2019); Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans, J. Control. Release (10.1016/j.jconrel.2019.06.029)
  • Villa Nova M, Nothnagel L, Thurn M, Travassos PB, Herculano LS, Bittencourt PRS, Novello CR, Bazotte RB, Wacker MG, Bruschi ML (2018); Development study of pectin/Surelease microparticles for the delivery of L-alanyl-L-glutamine dipeptide, Food Hydrocoll. (10.1016/j.foodhyd.2018.11.038)
  • Feczkó T, Piiper A, Ansar S, Blixt FW, Ashtikar M, Schiffmann S, Ulshöfer T, Parnham MJ, Harel Y, Israel LL, Lellouche JP, Wacker MG (2018); Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy, J. Control. Release 293: 63-72 (10.1016/j.jconrel.2018.11.017)
  • Nothnagel L and Jung F, Rossmanith T, Thurn M, Ashtikar M, Geisslinger G, Parnham MJ, Wacker MG (2018); Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2018.11.012)
  • Jung F and Nothnagel L, Gao F, Thurn M, Vogel V, Wacker MG (2018); A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling, Eur. J. Pharm. Biopharm. 127: 462-470 (10.1016/j.ejpb.2018.03.010)
  • Janas C, Kirsamer L, Mast MP, Agioni C, Gao F, Mäntele W, Dressman J, Wacker MG (2017); The dispersion releaser technology is an effective method to test the drug release from nanosized carriers, Eur. J. Pharm. Biopharm. 115: 73-83 (10.1016/j.ejpb.2017.02.006)
  • Beyer S and Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG (2016); Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques, J. Control. Release, 10(235): 352-364 (10.1016/j.jconrel.2016.06.013)
  • Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG (2016); Novel polymeric micelles for drug delivery: Material characterization and formulation screening, Int. J. Pharm. 509(1-2): 197-207 (10.1016/j.ijpharm.2016.05.029)
  • Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N, Wacker MG (2015); Drug release and targeting: The versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox, Pharm. Res. 32(12): 3986-3998 (10.1007/s11095-015-1759-2)
  • Villa Nova M, Janas C, Schmidt M, Ulshöfer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Bruschi ML, Wacker MG (2015); Nanocarriers for photodynamic therapy – Rational formulation design and medium-scale manufacture, Int. J. Pharm. 491(1-2): 250-260 (10.1016/j.ijpharm.2015.06.024)
  • Xie L, Beyer S, Vogel V, Wacker MG, Mäntele W (2015); Assessing the Drug Release from Nanoparticles: Overcoming the Shortcomings of Dialysis by Using Novel Optical Techniques and a Mathematical Model, Int. J. Pharm. 488(1-2): 108-119 (10.1016/j.ijpharm.2015.03.080)
  • Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG (2015); Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. 32(5): 1714-1726 (10.1007/s11095-014-1569-y)
  • Wacker MG, Altinok M, Urfels S, Bauer J (2014); Nanoencapsulation of superparamagnetic particles of iron oxide into human serum albumin nanoparticles, Beilstein J. Nanotechnol. 5: 2259-2266 (10.3762/bjnano.5.235)
  • Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C,Gehrmann M, Rödel C, Kreuter J, Rödel F (2013); Targeting by cmHsp70.1-antibody coated and Survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, J. Control. Release 172(1): 201-206 (10.1016/j.jconrel.2013.08.020)
  • Hofmann B, Rödl CB, Fischer AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Živković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D (2011); Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor, Br. J. Pharmacol. 165(7): 2304-2313 (10.1111/j.1476-5381.2011.01707.x)
  • Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V (2011); A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation, Int. J. Pharm. 414(1-2): 225-232 (10.1016/j.ijpharm.2011.04.046)
  • Löw K, Wacker M, Wagner S, Langer K, von Briesen H (2010); Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells, Nanomedicine 7(4): 454-463 (10.1016/j.nano.2010.12.003)
  • Preuss A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B (2010); Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems, J. Control. Release 148(1): 117-118 (10.1016/j.jconrel.2010.07.089)
  • Zheng SZ, Löw K, Wacker M, Wiehe A, Wagner S, Langer K, von Briesen H, Zou SQ (2010); Interaction and cytotoxicity of mTHPC and mTHPC complexes in Jurkat cells. Chin. J. Exp. Surg. 27: 13-22. [Article in Chinese]
  • Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Roeder B (2010); Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems, J. Photochem. Photobiol. B 101(3): 340-347 (10.1016/j.jphotobiol.2010.08.006)
  • Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K (2010); Photosensitizer loaded HSA nanoparticles I: Preparation and photophysical properties, Int. J. Pharm. 93(1-2): 253-62 (10.1016/j.ijpharm.2010.11)
  • Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roeder B (2009); Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigation  s, J. Photochem. Photobiol. B 96(1): 66-74 (0.1016/j.jphotobiol.2009.04.006)

 

Review articles and Editorials

  • Hermans A, Dorozynski P, Muzzio FJ, Li H, Nielsen S, Chen S, Reppas C, Klein S, Patel S, Wacker M, Thakker K, Pruessmann K, Seidlitz A, Ghosh TK, Yang Y, Willett D, Hochhaus G, Tay J, Liew CV, Heng PWS, Sun CC, Kraemer J, Marques MRC (2020); Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products, Diss. Tech. (10.14227/DT270220P52)
  • Wacker MG (2019); Frontiers in pharmaceutical nanotechnology, Beilstein J. Nanotechnology. (doi.org/10.3762/bjnano.10.244)
  • Fecioru E, Klein M, Krämer J, Wacker MG (2019); In vitro performance testing of nanoparticulate drug products for parenteral administration, Diss. Tech. (10.14227/DT260319P28)
  • Marques MRC, Choo Q, Ashtikar M, Rocha TC, Bremer-Hoffmann S, Wacker MG (2019); Nanomedicines – Tiny particles and big challenges, Adv. Drug Del. Rev. (10.1016/j.addr.2019.06.003)
  • Ashtikar M, Mäder K, Klein M, Wunderlich K, Lozach P-Y, Gao F, Mende S, Strasser C, Dennison T, Marenchino M, Wacker, MG (2019); LOEWE Workshop Particle Characterization in Medicine and Biology, Pharm. Front. (10.20900/pf20190002)
  • Nothnagel L, Wacker MG (2018); Mikro- und Nanoarzneiformen in Entwicklung und Qualitätskontrolle – Welche Methoden eignen sich für den Test auf Wirkstofffreisetzung – Teil 2, Pharm. Ind. 11/2018 (Article in German)
  • Nothnagel L, Wacker MG (2018); Mikro- und Nanoarzneiformen in Entwicklung und Qualitätskontrolle – Welche Methoden eignen sich für den Test auf Wirkstofffreisetzung – Teil 1, Pharm. Ind. 10/2018 (Article in German)
  • Nothnagel L, Wacker MG (2018); How to measure release from nanosized carriers, Eur. J. Pharm. Sci. (10.1016/j.ejps.2018.05.004)
  • Ashtikar M, Wacker MG (2018); Nanotherapeutics for wound healing – Lost in translation?, Adv. Drug Del. Rev. 129, 194-218  (10.1016/j.addr.2018.03.005)
  • Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines – What do we know?, Mat. Tod. Proc. 2, 214-217 (10.1016/j.matpr.2017.09.189)
  • Wacker MG, Proykova A, Santos GM (2016); Dealing with nanosafety around the globe – Regulation vs. Innovation, Int. J. Pharm. 509(1-2): 95-106 (10.1016/j.ijpharm.2016.05.015)
  • Bergs JW, Wacker MG, Hehlgans S, Piiper A, Multhoff G, Rödel C,Rödel F (2015); The role of recent nanotechnology in enhancing the efficacy of radiation therapy, Biochim. Biophys. Acta 1856(1): 130-143 (10.1016/j.bbcan.2015.06.008)
  • Wacker MG; Hund-Rinke K, Creutzenberg O (2015); Quo vadis Nano? Nanomaterialien in der pharmazeutische Produktentwicklung, Pharm. Ind. 76(7): 1134-1140 (Article in German)
  • Wacker MG (2014); Nanotherapeutics – Product Development Along the ‘Nanomaterial’ Discussion, J. Pharm. Sci. 103(3): 777-784 (10.1002/jps.23879)
  • Wacker M (2013); Nanocarriers for intravenous injection – The long hard road to the market, Int. J. Pharm. 457(1): 50-62 (10.1016/j.ijpharm.2013.08.079)

 

Patents and patent applications

  • Wacker MG, Beyer S, Parnham MJ, Maentele W, Vogel V, Xie (Kirsamer) L, Composition Comprising a Biocompatible and Biodegradable Polymer, Nanocarriers and a Drug and Methods of Making and Using the Same, PCT application 2016 (PCT/EP2016/076715)
  • Wacker MG, Janas C; Adapter für die Freisetzung disperser Arzneizubereitungen (Dispersion Releaser), German Patent 2015 (DE102013015522 A1) / PCT application 2014 (PCT/EP2014/002523)
  • Langer K, Wacker M, Röder B, Preuss A, Albrecht V, Gräfe S, Wiehe A, von Briesen H, Löw K, Wagner S; Nanoparticle carrier systems based on human serum albumin for photodynamic therapy (US 2011/0142948 A1)

 

Book chapters

  • Wacker MG, Janas C, Ferreira FS, Vieira FP, ‘Manufacturing and Safety Guidelines for Manufactured Nanomaterials in Pharmaceutics’ in Sarmento B and das Neves J (ed), ‘Biomedical applications of functionalized nanomaterials‘ (1st edn), Elsevier Publishing Group (Netherlands) (10.1016/B978-0-323-50878-0.00021-5)
  • Wacker MG, ‘Nanomedicines – A Scientific Toy or an Emerging Market?‘ in Vauthier C and Ponchel G (ed), ‘Polymer nanoparticles for nanomedicines: A Guide for Design, Preparation and Development‘ (1st edn), Springer International (Switzerland) (10.1007/978-3-319-41421-8_18)
  • Wacker MG, ‘Suspensionen – Parenteralia, Ophthalmika und perorale Suspensionen: Teilchengrößen-wachstum, Stabilität, Freisetzung‘ in Stieneker F (ed), ‘Partikel in der Pharmaproduktion: Messtechnik – Detektion und Charakterisierung – Regulatorische Anforderungen‘ (1st edn), Editio Canto Verlag (Germany)

 

Abstracts and presentations

  • Wacker MG (07-2020); Reverse-Engineering Nanomedicines, Malvern Webinar Series (Hosted in Singapore).
  • Wacker MG (06-2020); Nanomedicine in the Spotlight – Unlock your PK, APTI Virtual Seminar (Hosted in India).
  • Wallenwein CM (06-2020); A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes, SPDS Disso Research Presentations India 2020 Online (Hosted in India).
  • Wacker MG (05-2020); Nanomedicine 2020 – Tiny Giants Unleashed; ExplainMyResearch Virtual Conference (Hosted in Singapore).
  • Jung F (05-2020); Nanoparticles and Environmental Protection – A Gordian Knot?; ExplainMyResearch Virtual Conference (Hosted in Singapore).
  • Wacker MG (02-2020); Translational Nanotechnology – Performance Assays for the Next Generation, CRS Local Chapter India, Mumbai, India.
  • Wacker MG (12-2019); Dissolution of drug products containing nanomaterials, USP workshop, Rockville, USA.
  • Wacker MG (09-2019); Translational Nanomedicine – How to predict clinical performance?, Global Summit on Regulatory Science, Stresa, Italy.
  • Gao FG, Villa Nova M, Ashtikar M, Wacker MG (06-2019); Prediction of human pharmacokinetics of subcutaneously administered insulin formulations, PAGE conference, Stockholm (Sweden)
  • Jung F, Thurn M, Krollik K, Gao FG, Hering I, Eilbrecht E, Weiler M, Günday-Türeli N, Türeli E, Parnham MJ, Wacker MG (06-2019); Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods, PAGE Conference, Stockholm (Sweden)
  • Wacker MG (03-2019); Theranostic nanocarriers loaded with nerve growth factor enable enhanced brain recovery after stroke, European Conference on Pharmaceutics, Bologna (Italy)
  • Wacker MG (06-2018); Nanotechnology in translation – Define, design, produce!, Institute of Materials and Environmental Chemistry/Hungarian Academy of Sciences, Budapest (Hungary)
  • Gao F, Villa Nova M, Ashtikar M, Wacker MG (06-2018); Prediction of human pharmacokinetics of subcutaneously administered depot formulation using MBPK modeling, PAGE conference, Montreux (Switzerland)
  • Jung F, Nothnagel L, Gao F, Wacker MG (06-2018); Evaluation of release techniques for nanocarriers on the basis of IVIVC-PBPK modeling, PAGE conference, Montreux (Switzerland)
  • Wacker MG (03-2018); Challenges in the drug release testing of next-generation nanomedicines, CRS Indian Chapter Meeting, Mumbai (India)
  • Wacker MG (02-2018); Advances in Nanosized Drug Delivery – Lost in Translation?, LOSAN Drug Delivery Conference, Frankfurt (Germany)
  • Wacker MG (10-2017); Safety & Regulatory Aspects of Nanomedicines, National University of Singapore Workshop, Singapore
  • Wacker MG (2016); Designing nanocarriers for drug delivery, NRW-Nanokonferenz, Münster (Germany)
  • Wacker MG (2016); Challenges in the drug release testing of next generation nanomedicines, NanoBioMedizin Meeting, Frankfurt (Germany)
  • Nothnagel L, Thurn M, Wacker MG (2016); DoE-based development and in vitro drug release testing of TMP-001 loaded nanocarriers, GPEN Meeting, Lawrence (USA)
  • Jablonka L, Thurn M, Wacker MG (2016); In vitro drug release testing of liposomal temoporfin formulations with the dispersion releaser technology, GPEN Meeting, Lawrence (USA)
  • Wacker MG (2016), Designing Nanomedicines for the Market, DDF Summit, Berlin (Germany)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, PT Indonesia Workshop, Jakarta (Indonesia)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Matrix Analytical Technologies Workshop, Kuala Lumpur (Malaysia)
  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, LOSAN Drug Delivery Conference, Frankfurt (Germany)
  • Wacker MG (2015), Die neue Nanomedizin – Von der Idee zum Produkt, NanoBioMedizin Meeting, Frankfurt, Germany
  • Wacker MG (2015), Nanocarriers for Drug Delivery – Rational Formulation Design, 1st International Symposium on Drug Delivery Systems, Maringá, Brazil
  • Wacker MG (2015), Parenteralia, Ophthalmika und perorale Suspensionen – Stabilität, Teilchengrößenwachstum und Freisetzung, FAH Workshop – Pharmaproduktion und Partikel, Bonn, Germany
  • Wacker MG (2015), Nanocarriers for Cancer Therapy – Rational Formulation Design, Evonik-LOSAN Workshop, Darmstadt, Germany
  • Wacker MG (2015), Nanocarriers for Drug Delivery – Rational Formulation Design, DDF Global Summit, Düsseldorf, Germany
  • Wacker MG (2014), Rational Formulation Design – Nanomedizin mal anders!, DPhG, Freiburg, Germany
  • Janas C, Dressman JB, Wacker MG (2014), The Dispersion Releaser: An Optimal Tool for Selection of Colloidal Dosage Forms, GPEN Meeting, Helsinki, Finland
  • Beyer S, Gräfe S, Albrecht V, Wacker MG (2014), Accepting the Challenge of Scale-up – A New Approach for the Targeted Treatment of Colon Cancer based on Nanoparticles overcomes the Limitations of Batch Size, Controlled Release Socienty Annual Meeting, Chicago, USA
  • Wacker MG (2014), Rational Formulation Design – Nanomedizin mal anders!, Neue Potentiale für die Nanotechnologie in der Medizin, Darmstadt, Germany
  • Wacker MG, Parnham MJ (2014), Achieving a Good Working Relationship with an Academic Research Organization, Drug Delivery & Formulation Americas Summit, San Diego, USA
  • Wacker M (2013); Nanocarrier – Entwicklung und Optimierung innovativer Arzneistoffträger, PharmaForum Hessen 2013, Mainz, Germany
  • Wacker M (2013) Nanocarrier – Trends in Modern Formulation Development, LOSAN Innovative Dosage Forms in Development and Production Workshop, Essen (Germany)
  • Wacker M (2011); Nanopartikel – Eine neue Alternative in der peroralen Arzneistoffformulierung, Pharmaforum 2011 Saarland, St. Ingbert, Germany
  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation, 38th Annual Meeting and Exposition of the Controlled Release Society 2011, National Harbor, USA